Overview
Janssen-Cilag Polska is a pharmaceutical company that focuses on innovative medicine, particularly in oncology, immunology, and neuroscience. It has developed and received FDA approval for several treatments, including RYBREVANT FASPRO™ for EGFR-mutated non-small cell lung cancer, CAPLYTA® for major depressive disorder, and DARZALEX FASPRO® for high-risk smoldering multiple myeloma. The company also acquired Halda Therapeutics to enhance cancer treatment options.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2003-10-31. Active
76 1030 1508 0000 0008 1088 7079- 51 1030 1508 0000 0008 1088 7044
- 48 1030 1508 0000 0008 1088 7001
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 6, 2019 | Merger plan |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
973 tenders recorded as contractor: 164 national ($10,813,301) and 809 EU ($8,011,946,853).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 2, 2026 | Dostawa leków do chemioterapii i programów lekowych 2026-2028 | — | Wojewódzki Szpital Specjalistyczny We Wrocławiu | |
| Oct 2, 2026 | Dostawa leków programowych, onkologicznych, płynów infuzyjnych, erytropoetyny oraz kontrastów | — | Wojewódzki Szpital Specjalistyczny Nr 4 w Bytomiu | |
| Sep 30, 2026 | Dostawa produktów leczniczych i wyrobów medycznych do Wojskowego Instytutu Medycznego - PIB. | — | Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a management board consisting of one or two members, the members of the management board represent the company individually before public authorities and third parties, in court and out of court. In the case where the company's management board consists of three or more members, the company is represented by two members of the management board acting jointly, or by a member of the management board acting jointly with an independent commercial proxy or any of the joint commercial proxies.
Ownership
| Owner | Share value | Stake |
|---|---|---|
Johnson & Johnson International Financial Services Company | $6,766,612.64 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Radu Stefan Birsan-Hirtie (45)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Julie Enevold Brooker (54)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Przemysław Brzeski (53)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Iwona Gąsiorowska (50) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Marcin Soliwodzki (49) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| RTB HouseS.A. | $90,124,822.28 | rtbhouse.com | |
| OEX CursorS.A. | $72,834,175.54 | oexcursor.pl | |
| AMSS.A. | $58,787,543.95 | ams.com.pl | |
| Świat ZdrowiaS.A. | $44,069,308.57 | swiatzdrowiasa.pl | |
| MediaexpertS.A. | $39,887,162.29 | mediaexpert.pl |
Change history
| Date | Event |
|---|---|
| 2017-01-27 | PKD change (Added: 46.46.Z) |
| 2015-03-17 | PKD change (Removed: 72.30.Z, 73.10.F, 74.13.Z, 74.14.A, 74.40.Z, 74.84.B; Added: 62.03.Z, 63.11.Z, 63.99.Z, 70.21.Z, 70.22.Z, 72.19.Z, 73.11.Z, 73.20.Z) |
| 2007-08-21 | Address change (Szyszkowa 20, 02-285, Warszawa → Iłżecka 24, 02-135, Warszawa) |
| 2003-01-16 | Share capital change (50,000.00 PLN → 25,050,000.00 PLN) |
| 2003-01-16 | Name change (Jannsen-Cilag Polska → Janssen-Cilag Polska) |
FAQ
Last updated: 2026-09-28